White Paper

Dr. Reddy's API Offering*

• We offer Cabozantinib S-malate – Crystalline form N2 (Innovator form).
• Cabozantinib HCl is an alternate salt providing 505(b)(2) opportunities in the US and early launch opportunities in Europe, Brazil, Turkey, Mexico, and South Korea.
• Dr. Reddy’s proposed synthetic process is IP-compliant.
• We employ a quality-by-design (QbD) approach for efficient processes and high-quality output.
• Effective control strategy for avoiding potential genotoxic and carcinogenic impurities
• Assured process safety and scalability.
• A short lead time of 120-180 days from the purchase order date (PO).

To learn more about our API offerings, please read the Tech sheet on Cabozantinib API by filling out the contact form below.

Note: *Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale.